A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Ocular Infection

Interventions

DRUG

DCN01

Three serial applications per periocular region.

DRUG

Unisol

Three serial applications per periocular region.

Trial Locations (1)

Andover Eye Associates, Andover